Aratana therapeutics, inc. (PETX)
Income statement / TTM
Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Sep'12Jun'12
Revenues
Total revenues

38,729

35,412

40,963

25,571

25,821

25,573

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Licensing and collaboration revenue

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

500

0

0

0

-

-

-

0

-

-

Product sales

-

-

-

-

-

-

-

-

-

-

171

360

543

678

0

0

0

-

-

-

-

-

-

-

0

-

-

Total revenues

-

-

-

-

-

-

-

-

-

-

38,322

38,511

694

678

863

677

747

767

0

0

0

-

-

-

0

0

0

Costs and expenses
Cost of product sales

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of product sales

-

-

-

11,443

-

-

-

8,164

6,214

-

2,054

1,906

274

365

0

0

0

-

-

-

-

-

-

-

0

-

-

Royalty expense

4,751

3,865

3,771

2,866

2,304

1,821

1,166

744

411

106

75

79

82

84

86

80

74

72

0

0

0

-

-

-

0

-

-

Research and development

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

-

-

8,840

10,553

-

15,126

20,650

22,764

24,367

30,462

27,851

28,714

29,492

24,964

24,534

24,415

22,634

19,985

17,058

14,214

12,383

10,925

9,475

8,170

0

0

0

Selling, general and administrative

30,274

28,780

28,992

28,892

29,101

28,897

29,042

29,056

28,286

27,342

25,381

23,454

22,185

19,819

19,086

17,986

17,511

17,938

0

0

0

-

-

-

-

-

-

General and administrative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,976

4,172

0

0

0

In-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,157

1,157

0

0

-

0

-

-

-

-

Amortization of intangible assets

530

517

503

459

416

350

333

339

348

379

376

768

1,156

1,544

1,638

1,736

1,835

1,891

0

0

0

-

-

-

0

-

-

Impairment of intangible assets

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

In-process research and development

-

500

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of intangible assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Total costs and expenses

49,746

47,300

59,979

62,161

66,275

70,029

67,921

66,229

67,568

69,370

58,517

101,099

96,587

90,174

90,432

45,769

43,997

42,376

37,950

32,038

25,962

19,904

0

0

0

-

-

Total operating expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Loss from operations

-11,017

-11,888

-19,016

-36,590

-40,454

-44,456

-52,513

-56,944

-25,394

-30,819

-20,195

-62,588

-95,893

-89,496

-89,569

-45,092

-43,250

-41,609

-37,308

-31,439

-25,663

-19,781

-14,451

-12,342

0

0

0

Other income (expense)
Interest income

699

666

579

558

505

449

420

398

393

385

318

235

195

189

212

210

180

123

82

77

86

75

56

33

0

0

0

Interest expense

-

3,391

3,237

3,391

3,474

3,481

3,443

3,432

3,407

3,396

3,478

2,845

2,216

1,585

953

949

950

1,060

1,018

876

736

432

0

0

0

-

-

Other income (expense), net

-105

-109

-12

-16

-23

-22

291

282

288

255

-51

-37

3,140

5,140

7,586

7,576

4,495

2,287

-135

-81

167

478

0

0

0

-

-

Other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

Total other income (expense)

-1,944

-2,834

-2,670

-2,849

-2,992

-3,054

-2,732

-2,752

-2,726

-2,756

-3,211

-2,647

1,119

3,744

6,845

6,837

3,725

1,350

-1,071

-880

-483

121

410

423

0

0

0

Loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-85,752

-82,724

-38,255

-39,525

-40,259

-38,379

-32,319

-26,146

-19,660

0

0

0

-

-

Income tax benefit

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,698

-1,269

-1,112

-1,087

-1,443

-14,285

-13,684

-13,349

-12,722

0

0

0

-

-

Net income (loss)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Net loss

-12,961

-14,722

-21,686

-39,439

-43,446

-47,510

-55,245

-59,696

-28,120

-33,575

-23,097

-64,168

-93,347

-84,054

-81,455

-37,143

-38,438

-38,816

0

0

0

-

-

-11,919

0

0

0

Net loss per share, basic and diluted

-0.14

-0.18

0.19

-0.14

-0.19

-0.36

-0.21

-0.26

-0.34

-0.66

-0.38

0.61

-0.52

-0.38

-1.58

-0.23

-0.26

-0.29

-0.35

-0.32

-0.34

8.94

-0.22

-4.62

-4.73

-9.64

-10.21

Net income attributable to participating securities

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unaccreted dividends on convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

532

0

0

0

Net income (loss) attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-16,149

-14,549

0

0

0

Weighted average shares outstanding, basic and diluted

48,277

-

-

46,258

44,788

-

-

40,206

36,711

-

35,092

-

34,653

-

34,405

-

34,193

34,194

29,348

28,761

26,765

21,652

20,806

918

860

328

300

Weighted average shares outstanding, basic

-

-

47,310

-

-

-

42,445

-

-

-

-

34,762

-

-

-

34,278

-

-

-

-

-

-

-

-

-

-

-

Weighted average shares outstanding, diluted

-

-

47,485

-

-

-

42,445

-

-

-

-

34,938

-

-

-

34,278

-

-

-

-

-

-

-

-

-

-

-

Licensing and Collaboration [Member]
Total revenues

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product Sales [Member]
Total revenues

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-